BioCartis receives € 1,7M IWT grant for improved disease diagnosis

30-Jun-2014 - Belgium

Biocartis announced it received a grant of € 1.7M from the Flemish Government to further enhance the capabilities of its flagship platform Idylla™. With this grant the Flemish Agency for Innovation by Science and
Technology (IWT) affirms its belief in Biocartis’ cutting edge R&D.

Biocartis will use this grant to develop, amongst others, its hybrid multiplexing technology aimed at detecting and quantifying multiple biomarker types with a single Idylla™ test. Biocartis is currently developing oncology assays that can already detect tens of biomarkers of the same type. Looking ahead, Biocartis is working on the detection of multiple biomarker types in a single test. Today this can only be accomplished by using several individual tests, often performed on different diagnostic systems or even in separate laboratories, making it a very costly process. The hybrid multiplexing technology opens the door to cost-effective, simultaneous testing of several actionable biomarkers from a single patient sample, allowing precision medicine at affordable cost.

Geert Maertens, Chief Scientific Officer at Biocartis, stated: “The hybrid multiplexing project will strengthen our competitive position in the oncology field and open new opportunities in other disease areas such as infectious and genetic diseases”.

Other news from the department business & finance

Most read news

More news from our other portals

So close that even
molecules turn red...

Last viewed contents

Silence Therapeutics Issued New U.S. Patent Covering Fundamental RNA Interference Technology Currently in Several Clinical Trials - New Patent Broadens Company’s Existing Protection of Optimized RNAi Molecules Including Proprietary AtuRNAi Platform

Biofrontera received official review of its drug approval dossier for BF-200 ALA

Acambis extends Sanofi Pasteur licensing agreement on single-dose JE vaccine to India and Indian subcontinent

Exiqon A/S wins prestigious Ernst & Young Entrepreneur of the Year Award

Bio-Rad Announces Receipt of New Ruling in Applied Biosystems Patent Infringement Dispute

Sandoz completes acquisition of EBEWE Pharma, improving global patient access to affordable injectable cancer medicines - Sandoz to focus on quick and seamless integration for customers and employees

Eckert & Ziegler acquires Vitalea Science Inc. as Part of Strategic Move into Innovative Pharmaceutical Services

Albumin preserves kidney function and improves survival in abdominal infection of liver disease

Transition Therapeutics Announces Appointment of Vice-President of Clinical Operations

UCB to sell its U.S. specialty generics business Kremers Urban for US$ 1,525 million

Evotec and Novo Nordisk form research alliance in diabetes and obesity

CSL Behring Initiates Study of Subcutaneous Administration of C1-esterase Inhibitor in Patients with Hereditary Angioedema - Phase I/II study to establish safety and clinical pharmacology with various doses of subcutaneous formulation of human C1-esterase inhibitor